ICER Launches Customizable COVID-19 Cost-Effectiveness Model

The Institute for Clinical and Economic Review (ICER) announced the launch of a cloud-based platform that allows customization of model assumptions and inputs, enabling global health technology assessment (HTA) agencies to access ICER’s cost-effectiveness models. ICER aims to enhance the transparency of HTA assessments around the world and improve access for all HTA groups, especially those from lower and middle income countries. The platform further empowers the international HTA community to rapidly inform governmental decisions about drug pricing and coverage using models based on the most up-to-date science and methodology.

“Because many new drugs are launched first in the US, ICER is often the first HTA organization to perform a formal assessment — including independent economic modeling — of a new drug.” said Steven D. Pearson, MD, MSc, President of ICER. “We believe international HTA agencies will benefit from having access to ICER models in a customizable platform that allows those agencies to adapt the model inputs to reflect local conditions. Read more here.

(Source: ICER, October 9, 2020)